Aspen Neuroscience prices $15 IPO, raising $140.6 million
+2 new sources since this summary was written
Aspen Neuroscience, a clinical‑stage biotech developing autologous cell therapies for Parkinson’s disease, announced that it priced its initial public offering at $15.00 per share. The company sold 9,375,000 shares, generating gross proceeds of approximately $140.6 million, and will begin trading on Nasdaq under the ticker ASPE on October 30, 2026. Underwriters hold a 30‑day option to purchase up to an additional 1,406,250 shares.
Why it matters
The new capital will be used to advance the company’s lead candidate, sasineprocel, through later‑stage clinical trials, including a planned Phase 3 study. Investors now have the opportunity to acquire shares at the IPO price as trading commences.
Key facts
- 1The IPO was priced at $15.00 per share. tradingview.com
- 2Aspen offered 9,375,000 shares in the offering. tradingview.com
- 3Gross proceeds are expected to be about $140,625,000. tradingview.com
- 4Trading is scheduled to start on Nasdaq on October 30, 2026 under the ticker ASPE. tradingview.com
- 5Underwriters have a 30‑day option to buy up to 1,406,250 additional shares. tradingview.com
- 6The offering is expected to close on November 2, 2026, subject to customary closing conditions. stocktitan.net
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.